secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0000882095-22-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q1 revenue $6.6B (+3%), non-GAAP EPS $2.12 (+4%), GAAP EPS $0.02 due to $2.7B impairment
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.02 vs $1.37 Q1 2021 due to $2.7B IPR&D impairment; non-GAAP EPS $2.12, +4% YoY.
- Biktarvy sales $2.2B (+18%), oncology sales $420M (+60%) led by Trodelvy $146M (+103%) and cell therapy $274M (+43%).
- Veklury sales $1.5B (+5%); HIV total $3.7B (+2%); HCV sales $399M (-22%).
- Updated GAAP EPS guidance to $3.00-$3.50 from $4.70-$5.20; non-GAAP EPS and revenue guidance unchanged.
- Cash $6.8B; operating cash flow $1.8B includes $1.25B legal settlement; $725M Arcus opt-in payment, $352M buybacks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000010/0000882095-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000010/gild-20220428.htm
  HTML page:      https://secwatch.observer/filing/0000882095-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer